Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606303 | 1.00 | PDE10A (1.00) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL31597233 | 0.82 | PDE10A (0.70) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL1741719 | 0.81 | CYP19A1 (0.79) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL13377800 | 0.80 | PDE10A (0.67) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL4436213 | 0.78 | SREBF2 (0.67) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL252304 | 0.78 | PDE10A (0.64) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL15825002 | 0.78 | PDE10A (0.64) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL13020808 | 0.78 | PDE10A (0.64) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL31341159 | 0.78 | PDE10A (0.64) | PDE10AKDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL21366089 | 0.77 | PDE10A (0.63) | PDE10AKDM4EALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3564239-B9 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN INC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3564239-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | Shenzhen Immunova Pharmaceutical Co., Ltd. (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| EP-0974598-B1 | New erythromycin derivatives, process for making them and their use as medicines | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| US-20080139489-A1 | USE OF KETOLIDES FOR PREVENTING ARTERIAL THROMBOTIC COMPLICATIONS RELATED TO ATHEROSCLEROSIS | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| US-20080139489-A1 | USE OF KETOLIDES FOR PREVENTING ARTERIAL THROMBOTIC COMPLICATIONS RELATED TO ATHEROSCLEROSIS | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-6187928-B1 | TREATING FUNGAL DISEASES | THE ROCKEFELLER UNIVERSITY | 2001-02-13 | — | — | US | disclosed |
| US-6087510-A | Method of use of imidazolium cations | THE ROCKEFELLER UNIVERSITY (US) | 2000-07-11 | — | — | US | disclosed |
| US-5969150-A | FLUORESCENT COMPOUNDS FOR MEDICAL DIAGNOSIS, DRUGS AND LABELS OR FUNGICIDES AND VIRICIDES | THE ROCKEFELLER UNIVERSITY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5874587-A | FLUORESCENCE | THE ROCKEFELLER UNIVERSITY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0376848-A1 | Thiazolyl or oxazolyl substituted 1,2,5,6-tetrahydropyridine derivatives, process and intermediates for their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | PDE10A 2198/4885KDM4E 3048/4885ALDH1A1 2920/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | PDE10A 2198/4885KDM4E 3048/4885ALDH1A1 2920/4885 |
| US-20080139489-A1 | USE OF KETOLIDES FOR PREVENTING ARTERIAL THROMBOTIC COMPLICATIONS RELATED TO ATHEROSCLEROSIS | PCSK9, KHK, PCSK7 | PDE10A 1528/4885KDM4E 200/4885ALDH1A1 1171/4885 |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | PDE10A 3905/4885KDM4E 1715/4885ALDH1A1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.